+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class; Disease Condition; By Regions, Segments & Forecast, 2020-2026

  • ID: 5261911
  • Report
  • April 2020
  • Region: Global
  • 102 pages
  • Polaris Market Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Horizon Pharma Plc
  • JW Pharmaceutical
  • Merck & Co. Inc.
  • MORE
The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026, according to the study.

The report “Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020-2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.

Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.

Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.

However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market.

The global market is dominated by North America as the countries such as US and Canada have a large patient base, and also significant number of research activities are being conducted in this region. Many companies operating in this market segment are based in the US, and hence new products are primarily introduced in this regional segment. Gout affects around 8.3 million people in the United States, with prevalence in range of the 1-4%. The prevalence of gout is higher in African Americans as compared to Caucasians, and is projected to be increasing across all demographics in coming few years. Furthermore, government is also taking various measures to generated awareness and provide better healthcare facilities to the patient suffering with gout in this region.

Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grünenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region.

The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.

The analyst has segmented the Gout Therapeutics market report on the basis of level, application, material type, product type, product style and region.

Gout Therapeutics Drug Class Outlook (Revenue, USD Million, 2015-2026)
  • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Urate Lowering Agents
Gout Therapeutics Disease Condition Outlook (Revenue, USD Million, 2015-2026)
  • Acute
  • Chronic
Gout Therapeutics Regional Outlook (Revenue, USD Million, 2015-2026)
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Belgium
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Horizon Pharma Plc
  • JW Pharmaceutical
  • Merck & Co. Inc.
  • MORE
Chapter 1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

Chapter 2. Executive Summary
2.1. Market Highlights

Chapter 3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

Chapter 4. Market Analysis
4.1. Overview
4.2. Gout Therapeutics Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Geriatric Population
4.2.1.2. Increasing incidence and prevalence of gout
4.2.1.3. Growing research and development activities
4.2.2. Restraints and Challenges
4.2.2.1. High cost of new and improved drugs
4.2.2.2. Patent expiry of various blockbuster drugs
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (High)
4.3.3. Bargaining Power of Buyers (High)
4.3.4. Threats of Substitute (Moderate)
4.3.5. Rivalry Among The Existing Competitors (Moderate)
4.4. PESTLE Analysis
4.5. Gout Therapeutics Market Industry trends
4.5.1. Newer treatments for gout
4.6. Competitive Ranking Analysis

Chapter 5. Gout Therapeutics Market Assessment by Drug Class
5.1. KEY FINDINGS
5.2. Introduction
5.2.1. Global Gout Therapeutics Market, By Type, 2015-2026 (USD Million)
5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.1. Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million)
5.3.2. North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.3. Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.4. Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.5. LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.3.6. MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million)
5.4. Corticosteroids
5.4.1. Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million)
5.4.2. North America: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.3. Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.4. Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.5. LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.4.6. MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million)
5.5. Colchicine
5.5.1. Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million)
5.5.2. North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.3. Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.4. Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.5. LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.5.6. MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million)
5.6. Urate Lowering Agents
5.6.1. Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million)
5.6.2. North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.3. Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.4. Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.5. LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)
5.6.6. MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million)

Chapter 6. Gout Therapeutics Market Assessment by Disease Condition
6.1. KEY FINDINGS
6.2. Introduction
6.2.1. Global Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
6.3. Acute Gout
6.3.1. Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
6.3.2. North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.3. Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.4. Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.5. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.3.6. MEA: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4. Chronic
6.4.1. Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million)
6.4.2. North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.3. Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.4. Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.5. LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
6.4.6. MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million)

Chapter 7. Gout Therapeutics Market Assessment by Geography
7.1. KEY FINDINGS
7.2. Introduction
7.2.1. Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million)
7.3. NORTH AMERICA
7.3.1. North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.3.2. North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.3. North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.3.4. U.S.
7.3.4.1. U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.4.2. U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.3.5. Canada
7.3.5.1. Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.3.5.2. Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4. EUROPE
7.4.1. Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.4.2. Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.3. Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.4. Germany
7.4.4.1. Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.4.2. Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.5. UK
7.4.5.1. UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.5.2. UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.6. France
7.4.6.1. France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.6.2. France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.7. Italy
7.4.7.1. Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.7.2. Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.8. Spain
7.4.8.1. Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.8.2. Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.9. Belgium
7.4.9.1. Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.9.2. Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.4.10.2. Rest of Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5. ASIA-PACIFIC
7.5.1. Asia Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.5.2. Asia Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.3. Asia Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.4. China
7.5.4.1. China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.4.2. China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.5. India
7.5.5.1. India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.5.2. India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.6. Japan
7.5.6.1. Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.6.2. Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.7. South Korea
7.5.7.1. South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.7.2. South Korea: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.8. Australia
7.5.8.1. Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.8.2. Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.5.9. Rest of APAC
7.5.9.1. Rest of APAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.5.9.2. Rest of APAC: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6. LATIN AMERICA
7.6.1. Latin America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.6.2. Latin America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.3. Latin America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.4. Brazil
7.6.4.1. Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.4.2. Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.5. Mexico
7.6.5.1. Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.5.2. Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.6.6. Rest of LATAM
7.6.6.1. Rest of LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.6.6.2. Rest of LATAM: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7. MIDDLE EAST AND AFRICA
7.7.1. Middle East & Africa: Gout Therapeutics Market, by Country, 2015-2026 (USD Million)
7.7.2. Middle East & Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.3. Middle East & Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.4. South Africa
7.7.4.1. South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.4.2. South Africa: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.5.2. Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)
7.7.6. Rest of Middle East and Africa
7.7.6.1. Rest of MEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million)
7.7.6.2. Rest of MEA: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million)

Chapter 8. Competitive Landscape
8.1. Agreements, Collaborations, Product Developments and launch Analysis
8.1.1. Strategic Analysis - Gout Therapeutics Market
8.2. Prouct/Service Launch
8.3. Partnerships/Collaborations/Agreements
8.4. Approvals
8.5. Others

Chapter 9. Company Profiles
9.1. AstraZeneca
9.1.1. Business Overview
9.1.2. Financial Snapshot
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. Horizon Pharma Plc
9.2.1. Business Overview
9.2.2. Financial Snapshot
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Takeda Pharmaceutical Company Limited
9.3.1. Business Overview
9.3.2. Financial Snapshot
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. GlaxoSmithKline plc
9.4.1. Business Overview
9.4.2. Financial Snapshot
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Novartis AG
9.5.1. Business Overview
9.5.2. Financial Snapshot
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. Merck & Co. Inc.
9.6.1. Business Overview
9.6.2. Financial Snapshot
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Teijin Pharma Limited
9.7.1. Business Overview
9.7.2. Financial Snapshot
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Regeneron Pharmaceuticals, Inc.
9.8.1. Business Overview
9.8.2. Financial Snapshot
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Ironwood Pharmaceuticals, Inc.
9.9.1. Business Overview
9.9.2. Financial Snapshot
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. JW Pharmaceutical
9.10.1. Business Overview
9.10.2. Financial Snapshot
9.10.3. Products and Services
9.10.4. Recent Developments
9.11. Selecta Biosciences, Inc.
9.11.1. Business Overview
9.11.2. Financial Snapshot
9.11.3. Products and Services
9.11.4. Recent Developments
9.12. Grunenthal Group
9.12.1. Business Overview
9.12.2. Financial Snapshot
9.12.3. Products and Services
9.12.4. Recent Developments
Note: Product cover images may vary from those shown
3 of 3
  • AstraZeneca
  • Horizon Pharma Plc
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co. Inc.
  • Teijin Pharma Limited
  • Regeneron Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc.
  • JW Pharmaceutical
  • Selecta Biosciences Inc.
  • Grunenthal Group
Note: Product cover images may vary from those shown
Adroll
adroll